Come and talk to our Senior Scientist Sandra Ekstedt when she’s presenting her poster on OXC-201, a potential breakthrough for the treatment of IPF (Pulmonary fibrosis) at ERS in Milan on the 10th of September. The poster title is “Inhibiting OGG1, a new strategy for the treatment of IPF, blocking inflammatory and fibrotic cascades” and it is presentedin the session “New insights and biomarkers in pulmonary fibrosis and lung cancer” between 12:30 – 14:00. Do not miss this opportunity to learn more about OXC-201 including our patient-derived ex vivo model.
OXC-201 is a small molecule inhibitor of OGG1, a potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), other fibrotic conditions and inflammatory diseases. By targeting the DNA repair enzyme OGG1 (8-oxo guanine DNA glycosylase-1), OXC-201 inhibits binding of OGG1 to DNA and thereby the modulation of gene transcription. OGG1 plays a significant role in modulating inflammation and fibrogenesis; genetic downregulation or chemical inhibition of OGG1 has been shown to protect against inflammation and fibrosis in several experimental disease models. OXC-201 is patent protected and Oxcia AB has exclusive rights under the patent to develop and commercialize OXC-201.
The EIC (European Innovation Council) has awarded Oxcia AB a grant of 2.5 million euros within the EIC-Transition program which finances the next phase of the development of OXC-201.
ERS, the International Congress of the European Respiratory Society, will take place at Allianz MiCo, Milan, Italy between 9-13 September, 2023.
The ERS publishes academic journals and books as well as hosting events aimed at educating health professionals, covering the latest in respiratory clinical care, science, education and research. If you are at the meeting and are interested in OXC-201, please reach out to Sandra.